Clinical Insights: Experiences With Amivantamab-Lazertinib in EGFR-Mutant NSCLC

Video content above is prompted by the following:

Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC

Background

• Discussion between Alexander Spira, MD, PhD, FACP, FASCO, and Randi Rabin, MPH, MSc, PA-C
• Topic: Prevention of moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced non–small cell lung cancer treated with amivantamab plus lazertinib
• Referenced data from the COCOON trial presented at the European Lung Cancer Congress 2025

Clinical Experience

• Practitioners have extensive experience with amivantamab and lazertinib across multiple clinical trials (COCOON, CHRYSALIS 2, SKIPPirr, PALOMA 2 and 3).
• Overall positive experience reported for both providers and patients
• “Fantastic overall survival data” noted

Evolving Treatment Focus

• Field shifting from solely focusing on response rates and survival metrics to also emphasizing:
• Management of adverse events
• Quality of life measures
• Rationale: Improved tolerability increases adherence, which is essential for drug efficacy.

Patient Outcomes

• Patients on these medications reportedly maintain active lifestyles (travel, community involvement, physical activities).
• Quality of life improvements allow patients to continue normal activities while undergoing treatment.

Current Research Direction

• Focus on optimizing management rather than just administering treatment
• Specifically discussing the COCOON trial’s findings on skin/dermatologic adverse event management
• Related research includes infusion-related reaction management from the SKIPPirr trial

This summary reflects a discussion about managing adverse effects to improve both efficacy and quality of life for patients receiving amivantamab plus lazertinib combination therapy.